Baidu
map

泌尿外科

订阅

MedSci主页 / 所有栏目 / 泌尿外科

Appl Immunohistochem Mol Morphol：免疫组化技术在前列腺病灶活检应用中的评估

2019-01-19 AlexYang MedSci原创

前列腺免疫组化评估
关注

免疫组化（IHC）在前列腺病灶评估中的使用还没有常规化，且其价值还没有评估。最近，有研究人员提取了2011年到2017年的病理组织切片报告，并对其进行了回顾和分析。研究共包括了4477个活检样本。这些样本通过病理严重程度分类（染色百分比），群体包括1184名良性案例（42%）；168个前列腺上皮内瘤案例（68%）；323个疑似案例（93%）；一级癌症（WHO1）：900 (78%)； 二级癌症(W

免疫组化（IHC）在前列腺病灶评估中的使用还没有常规化，且其价值还没有评估。最近，有研究人员提取了2011年到2017年的病理组织切片报告，并对其进行了回顾和分析。

研究共包括了4477个活检样本。这些样本通过病理严重程度分类（染色百分比），群体包括1184名良性案例（42%）；168个前列腺上皮内瘤案例（68%）；323个疑似案例（93%）；一级癌症（WHO1）：900 (78%)； 二级癌症(WHO2)： 840 (60%)；WHO3癌症： 451 (54%)；WHO4 癌症： 363 (46%)；WHO5癌症： 215 (56%)；癌症等级不能精确确定： 33 (52%)。其中，2个医院分别包括2716个活检案例和1761个活检案例，分别包括了10183和14852个IHC。具有IHC的案例在过去4年时间里减少（在两个医院分别为57%到45%和79%到73%）。35名病理学家解读了大于20个案例，并且一起解释了4418个案例（范围21-415，均值为88）。在4418个案例中，总共进行了2476个IHCs（5.6个/案例）。对35名病理学家来说，每个案例的IHCs平均值/中值/SD/最大值/最小值分别为5.6/4.1/3.9/15.2/0.9。高IHC使用者比低IHC使用者具有更高的恶性肿瘤的可能，但是并不明显。

最后，研究人员指出，IHC在良性和恶性肿瘤中最经常使用，并且依赖于病理学家和医院。然而，上述情况与WHO1癌症发生率无关。另外，诊断频率信息能够帮助确定合理的IHC使用。

原始出处：

Bonert M， El-Shinnawy I， Rahman M et al. Immunohistochemistry Use by Diagnostic Category and Pathologist in 4477 Prostate Core Biopsy Sets Assessed at Two Hospitals. Appl Immunohistochem Mol Morphol. 8 Jan 2019.

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1703640, encodeId=37af1e036402a, content=<a href='/topic/show?id=9b00886536' target=_blank style='color:#2F92EE;'>#HIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8865, encryptionId=9b00886536, topicName=HIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=133330532258, createdName=yuanming17, createdTime=Thu Aug 22 01:18:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278120, encodeId=5b6612e8120ae, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 21 05:18:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438907, encodeId=0339143890e92, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jan 21 05:18:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358677, encodeId=fd593586e7b9, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Jan 20 06:42:50 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358648, encodeId=c5f135864805, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sat Jan 19 17:07:31 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358640, encodeId=28153586404f, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Jan 19 14:29:06 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-08-22 yuanming17

    #HIS#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1703640, encodeId=37af1e036402a, content=<a href='/topic/show?id=9b00886536' target=_blank style='color:#2F92EE;'>#HIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8865, encryptionId=9b00886536, topicName=HIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=133330532258, createdName=yuanming17, createdTime=Thu Aug 22 01:18:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278120, encodeId=5b6612e8120ae, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 21 05:18:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438907, encodeId=0339143890e92, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jan 21 05:18:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358677, encodeId=fd593586e7b9, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Jan 20 06:42:50 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358648, encodeId=c5f135864805, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sat Jan 19 17:07:31 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358640, encodeId=28153586404f, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Jan 19 14:29:06 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-01-21 仁心济世

    #活检#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1703640, encodeId=37af1e036402a, content=<a href='/topic/show?id=9b00886536' target=_blank style='color:#2F92EE;'>#HIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8865, encryptionId=9b00886536, topicName=HIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=133330532258, createdName=yuanming17, createdTime=Thu Aug 22 01:18:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278120, encodeId=5b6612e8120ae, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 21 05:18:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438907, encodeId=0339143890e92, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jan 21 05:18:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358677, encodeId=fd593586e7b9, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Jan 20 06:42:50 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358648, encodeId=c5f135864805, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sat Jan 19 17:07:31 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358640, encodeId=28153586404f, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Jan 19 14:29:06 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-01-21 zhouqu_8

    #免疫组化#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1703640, encodeId=37af1e036402a, content=<a href='/topic/show?id=9b00886536' target=_blank style='color:#2F92EE;'>#HIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8865, encryptionId=9b00886536, topicName=HIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=133330532258, createdName=yuanming17, createdTime=Thu Aug 22 01:18:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278120, encodeId=5b6612e8120ae, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 21 05:18:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438907, encodeId=0339143890e92, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jan 21 05:18:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358677, encodeId=fd593586e7b9, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Jan 20 06:42:50 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358648, encodeId=c5f135864805, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sat Jan 19 17:07:31 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358640, encodeId=28153586404f, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Jan 19 14:29:06 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-01-20 1e145228m78(暂无匿称)

    学习了，谢谢作者分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1703640, encodeId=37af1e036402a, content=<a href='/topic/show?id=9b00886536' target=_blank style='color:#2F92EE;'>#HIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8865, encryptionId=9b00886536, topicName=HIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=133330532258, createdName=yuanming17, createdTime=Thu Aug 22 01:18:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278120, encodeId=5b6612e8120ae, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 21 05:18:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438907, encodeId=0339143890e92, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jan 21 05:18:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358677, encodeId=fd593586e7b9, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Jan 20 06:42:50 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358648, encodeId=c5f135864805, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sat Jan 19 17:07:31 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358640, encodeId=28153586404f, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Jan 19 14:29:06 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-01-19 Janeinair

    学习学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1703640, encodeId=37af1e036402a, content=<a href='/topic/show?id=9b00886536' target=_blank style='color:#2F92EE;'>#HIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8865, encryptionId=9b00886536, topicName=HIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=133330532258, createdName=yuanming17, createdTime=Thu Aug 22 01:18:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278120, encodeId=5b6612e8120ae, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 21 05:18:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438907, encodeId=0339143890e92, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jan 21 05:18:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358677, encodeId=fd593586e7b9, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Jan 20 06:42:50 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358648, encodeId=c5f135864805, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sat Jan 19 17:07:31 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358640, encodeId=28153586404f, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Jan 19 14:29:06 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-01-19 1e145228m78(暂无匿称)

    学习了，谢谢作者分享!

    0

相关资讯

Urology：核磁共振成像确定的前列腺特异性抗原密度能够显著的改善前列腺癌活检的风险预测

最近，有研究人员评估了核磁共振成像（MRI）确定的前列腺癌特异性抗原（PSA）密度的预测价值和MRI对临床显著性前列腺癌（PCa）检测的解释能力情况。研究人员回顾性的分析了2014年9月和2016年12月之间研究人员所在单位的相关数据，这些数据是关于那些在活检之间接受前列腺MRI的男性患者数据，排除了那些积极监控的患者（n=372）。研究人员利用MRI确定的PSA密度、单独PSA和前列腺癌预防试验

Oncogene：Par3功能的丧失能够促进前列腺肿瘤的发生

尽管细胞极性在上皮肿瘤形成过程中具有重要的作用，然而细胞极性的丢失在前列腺肿瘤形成以及潜在的机制方面还不清楚。最近，有研究人员利用条件敲除小鼠模型，发现极性蛋白Par3极性的丢失能够增加前列腺上皮细胞的生长，提高基底细胞对称细胞分化，并在腔室细胞中随机分配纺锤体方向，从而引起高等级前列腺上皮内瘤（PIN）的发展。同时，Par3功能的丢失能够导致Par3/merlin/Lats1复合物的分离，进一步

你知道自己的前列腺健康指数吗？

前列腺癌（PCa）是男性第二大常见恶性肿瘤，也是导致死亡的第五大癌症。 基于前列腺特异性抗原（PSA）检测的前列腺癌筛查可以帮助早期发现肿瘤，但越来越多的研究证明，尽管PSA具有较好的组织特异性，但其肿瘤特异性较差，会引起过度诊断和过度治疗。

CLIN CHEM：前列腺癌风险相关的单核苷酸多态性影响前列腺特异性抗原糖基化及其功能

前期，遗传相关研究报道染色体19q13.3的单核苷酸多态性（SNPs）与前列腺癌（PCa）风险相关。最近，据报道，编码前列腺特异性抗原（PSA）的激肽释放酶相关肽酶3（KLK3）基因的外显子3中的rs61752561SNP（Asp84Asn取代）与PCa风险密切相关（P = 2.3×10 -8）。然而，有关rs61752561 SNP对PCa风险的生物学贡献尚未阐明。

盘点：前列腺癌盘点

前列腺是男性生殖器附属腺中最大的实质性器官。由前列腺组织和肌组织构成。前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌（腺泡腺癌）、导管腺癌、尿路上皮癌、鳞状细胞癌、腺鳞癌。其中前列腺腺癌占95%以上，因此，通常我们所说的前列腺癌就是指前列腺腺癌。梅斯医学小编整理了近期前列腺癌的研究进展，与大家一起分享学习！【1

Sci Rep：一个前列腺来源的共生表皮葡萄球菌菌株能够预防和减轻UPEC感染诱导的慢性前列腺炎

慢性前列腺炎/慢性盆腔疼痛综合症（CP/CPPS）是一种常见的综合症，并且治疗方法有限且发病原因未知。之前，有研究人员确定了疾病起始中病理感染的一个潜在角色。即从CP/CPPS患者中分离的尿路致病性大肠杆菌菌株CP1的尿道内感染能够诱导小鼠前列腺炎和触觉异常性疼痛。研究人员同样阐释了一个从健康个体分离的前列腺特异性表皮葡萄球菌NPI（非疼痛诱导）在小鼠模型中能够减少疼痛和炎症。最近，有研究人员关注

Baidu
map
Baidu
map
Baidu
map